259 related articles for article (PubMed ID: 21350811)
1. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies.
Tanaka S; Arii S
J Gastroenterol; 2011 Mar; 46(3):289-96. PubMed ID: 21350811
[TBL] [Abstract][Full Text] [Related]
2. Molecular targeted therapies in hepatocellular carcinoma.
Tanaka S; Arii S
Semin Oncol; 2012 Aug; 39(4):486-92. PubMed ID: 22846865
[TBL] [Abstract][Full Text] [Related]
3. Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science.
Tanaka S; Arii S
Int J Clin Oncol; 2010 Jun; 15(3):235-41. PubMed ID: 20505971
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target.
Lin D; Wu J
World J Gastroenterol; 2015 Nov; 21(42):12171-8. PubMed ID: 26576101
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy for hepatocellular carcinoma: current situation and prospect.
Wang Z; Zhang G; Wu J; Jia M
Drug Discov Ther; 2013 Aug; 7(4):137-43. PubMed ID: 24071575
[TBL] [Abstract][Full Text] [Related]
6. Molecular targeted therapy for hepatocellular carcinoma: current and future.
Shin JW; Chung YH
World J Gastroenterol; 2013 Oct; 19(37):6144-55. PubMed ID: 24115810
[TBL] [Abstract][Full Text] [Related]
7. Advanced hepatocellular carcinoma. Review of targeted molecular drugs.
Alves RC; Alves D; Guz B; Matos C; Viana M; Harriz M; Terrabuio D; Kondo M; Gampel O; Polletti P
Ann Hepatol; 2011; 10(1):21-7. PubMed ID: 21301005
[TBL] [Abstract][Full Text] [Related]
8. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
9. The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target.
Qin CD; Ma DN; Zhang SZ; Zhang N; Ren ZG; Zhu XD; Jia QA; Chai ZT; Wang CH; Sun HC; Tang ZY
Cell Death Dis; 2018 May; 9(5):486. PubMed ID: 29706627
[TBL] [Abstract][Full Text] [Related]
10. ZnAs@SiO
Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
[No Abstract] [Full Text] [Related]
11. Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications.
Frenette C; Gish R
World J Gastroenterol; 2012 Feb; 18(6):498-506. PubMed ID: 22363115
[TBL] [Abstract][Full Text] [Related]
12. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.
Pinyol R; Montal R; Bassaganyas L; Sia D; Takayama T; Chau GY; Mazzaferro V; Roayaie S; Lee HC; Kokudo N; Zhang Z; Torrecilla S; Moeini A; Rodriguez-Carunchio L; Gane E; Verslype C; Croitoru AE; Cillo U; de la Mata M; Lupo L; Strasser S; Park JW; Camps J; Solé M; Thung SN; Villanueva A; Pena C; Meinhardt G; Bruix J; Llovet JM
Gut; 2019 Jun; 68(6):1065-1075. PubMed ID: 30108162
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.
Cervello M; McCubrey JA; Cusimano A; Lampiasi N; Azzolina A; Montalto G
Oncotarget; 2012 Mar; 3(3):236-60. PubMed ID: 22470194
[TBL] [Abstract][Full Text] [Related]
14. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
15. Tex10 is upregulated and promotes cancer stem cell properties and chemoresistance in hepatocellular carcinoma.
Xiang X; Deng L; Xiong R; Xiao D; Chen Z; Yang F; Liu K; Feng G
Cell Cycle; 2018; 17(11):1310-1318. PubMed ID: 30045663
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
18. Advances in the study of molecularly targeted agents to treat hepatocellular carcinoma.
Chen J; Gao J
Drug Discov Ther; 2014 Aug; 8(4):154-64. PubMed ID: 25262594
[TBL] [Abstract][Full Text] [Related]
19. Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.
Gish RG; Finn RS; Marrero JA
Clin Adv Hematol Oncol; 2013 Apr; 11 Suppl 5():1-22; quiz 2 p following p22. PubMed ID: 23881427
[TBL] [Abstract][Full Text] [Related]
20. Positive feedback loop between cancer stem cells and angiogenesis in hepatocellular carcinoma.
Yao H; Liu N; Lin MC; Zheng J
Cancer Lett; 2016 Sep; 379(2):213-9. PubMed ID: 27108065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
